{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:34:15Z","timestamp":1791614055461,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004820","name":"Mochida Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.resinv.2025.101340","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T04:05:46Z","timestamp":1765771546000},"page":"101340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-5459","authenticated-orcid":false,"given":"Yasuhiro","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-9605","authenticated-orcid":false,"given":"Osamu","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1180-9262","authenticated-orcid":false,"given":"Takeshi","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Minatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Orido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Sakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.101340_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1296890","article-title":"Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment","volume":"11","author":"Althobiani","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2025.101340_bib2","article-title":"Current Understanding of Pulmonary Fibrosis: Pathogenesis, Diagnosis, and Therapeutic Approaches","volume":"2025","author":"Cui","year":"2025","journal-title":"Can Respir J"},{"key":"10.1016\/j.resinv.2025.101340_bib3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/life14091203","article-title":"Converging pathways: a review of pulmonary hypertension in interstitial lung disease","volume":"14","author":"Lawrence","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.resinv.2025.101340_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101340_bib5","article-title":"JCS\/JPCPHS 2025 Guideline on the Management of Pulmonary Thromboembolism","year":"2025","journal-title":"Deep Venous Thrombosis, and Pulmonary Hypertension"},{"key":"10.1016\/j.resinv.2025.101340_bib6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101340_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/ph16030418","article-title":"Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease","volume":"16","author":"Gonzales","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.resinv.2025.101340_bib8","article-title":"Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future","volume":"10","author":"Arslan","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2025.101340_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12405","article-title":"The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: diagnosis, symptoms, impacts, and treatments","volume":"14","author":"Piccari","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1016\/j.resinv.2025.101340_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12890-024-03141-3","article-title":"Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis","volume":"24","author":"Heresi","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2025.101340_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013310","article-title":"Hypoxic pulmonary vasoconstriction and the diffusing capacity in pulmonary hypertension secondary to idiopathic pulmonary fibrosis","volume":"8","author":"Sakao","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.resinv.2025.101340_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/690017","article-title":"Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis","volume":"7","author":"Prins","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.resinv.2025.101340_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0220-2021","article-title":"Recent advances in the management of pulmonary hypertension with interstitial lung disease","volume":"31","author":"Waxman","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2025.101340_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002161","article-title":"Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review","volume":"11","author":"Bongiovanni","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2025.101340_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101340_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: the INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101340_bib17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.resinv.2024.07.020","article-title":"Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease","volume":"62","author":"Sakao","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.101340_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacasi.2024.01.009","article-title":"Pulmonary Hypertension With Interstitial Pneumonia: Initial Treatment Effectiveness and Severity in a Japan Registry","volume":"4","author":"Tanabe","year":"2024","journal-title":"JACC Asia"},{"key":"10.1016\/j.resinv.2025.101340_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/688059","article-title":"An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension","volume":"6","author":"Zamanian","year":"2016","journal-title":"Pulm Circ"},{"key":"10.1016\/j.resinv.2025.101340_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.101340_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2025.101340_bib22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101340_bib23","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1007\/s12325-025-03215-6","article-title":"Progressive Pulmonary Fibrosis: Current Status in Terminology and Future Directions","volume":"42","author":"Kondoh","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.101340_bib24","first-page":"172","article-title":"Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan","volume":"7","author":"Huang","year":"2013","journal-title":"Biosci Trends"},{"key":"10.1016\/j.resinv.2025.101340_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.680997","article-title":"Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response","volume":"8","author":"Bowman","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2025.101340_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12931-022-02273-6","article-title":"Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis","volume":"23","author":"Choi","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.101340_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.resinv.2023.09.003","article-title":"Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Takei","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.101340_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.resinv.2019.03.006","article-title":"Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia","volume":"57","author":"Yamakawa","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.101340_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12890-024-03264-7","article-title":"Evaluating the diagnostic and prognostic utility of serial KL-6 measurements in connective tissue disease patients at risk for interstitial lung disease: correlations with pulmonary function tests and high-resolution computed tomography","volume":"24","author":"\u00c1lvarez Troncoso","year":"2024","journal-title":"BMC Pulm Med"}],"updated-by":[{"DOI":"10.1016\/j.resinv.2025.101365","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000}},{"DOI":"10.1016\/j.resinv.2025.101365","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:04:19Z","timestamp":1773896659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2212534525001959"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.101340","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.101340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101340"}}